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Abstract
Acne vulgaris is a common dermatological disorder, one that is frequently associated with depression, anxiety and
other psychological sequelae. In recent years there has been an increasing focus on the extent to which oxidative
stress is involved in the pathophysiology of acne. Emerging studies have shown that patients with acne are under
increased cutaneous and systemic oxidative stress. Indeed, there are indications that lipid peroxidation itself is a
match that lights an inflammatory cascade in acne. The notion that lipid peroxidation is a ‘starter gun’ in acne is
not a new one; here we review the nearly 50-year-old lipid peroxidation theory and provide a historical perspective
to the contemporary investigations and clinical implications.
In addition, we present a novel hypothesis in which lipid peroxidation may be priming an increased susceptibility
to co-morbid depression and anxiety in those with acne. The emerging research on the systemic burden of oxida-
tive stress in acne sheds further light on the brain-skin axis. The recent findings also suggest potential avenues of
approach for the treatment of acne via specific nutrients, dietary modifications, oral and topical interventions.
Introduction
Acne vulgaris is a common disease in developed nations,
one that has increased in frequency in the last half cen-
tury, particularly among adult women [1]. While the
experience of acne may not be life threatening per se, it
does carry with it significant psychological disability.
Indeed the psychological sequela of acne includes higher
rates of clinical depression - up to three times higher
than the general population [2]. Higher levels of anxiety,
anger, suicidal thoughts and even suicide itself have
been noted [3-7]. Evaluations have determined that
patients with acne have a more significant impairment
of mental health than many other chronic medical con-
ditions, including epilepsy and diabetes [8].
Despite technological advances and an increased
degree of sophistication within experimental dermatol-
ogy, the precise mechanisms of the acne process remain
elusive. In general terms, acne is characterized by sebum
overproduction, follicular hyperkeratinization, and an
increased release of inflammatory-mediating chemicals.
Androgens, microbes and other pathogenetic influences
are also at work in the development of acne [9,10].
In the past, it was thought that follicular plugging
(comedones) preceded Propionibacterium acnes
(P. acnes) colonization, which subsequently resulted in
inflammation (papules and pustules). This sequence of
events has been called into question in recent years. It
has been discovered that subclinical inflammatory events
are occurring in acne-prone skin even prior to hyper-
proliferative and abnormal differentiation events [11,12].
The reason for elevated pro-inflammatory factors, such
as interleukin-1 (IL-1), around the clinically normal
pilosebaceous follicles of acne patients remains
unknown. At this point it simply highlights that the
release of inflammatory chemicals is indeed one of the
earliest events to occur in the acne process. Further-
more, oxidative stress within the pilosebaceous unit
alters the environment from one that is unsuitable to
harbor anaerobic bacteria to one that is perfectly suited
for the colonization of such species [13]. P. acnes,o n c e
thought to be the initiating factor of inflammatory acne,
might never make the pilosebaceous unit its home were
it not for this initial inflammatory insult to the sebum.
Oxidation of sebum alters oxygen tension in the follicle,
resulting in the micro-aerophilic environment required
for P. acnes to survive. Apparently, inflammation and
oxidative stress might set the stage for all subsequent
pathogenic factors leading to acne.
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One plausible mechanism driving the early release of
inflammatory mediators is that described by the near
half-century-old lipid peroxidation theory of acne. In
1965, University of Chicago investigator Allan L. Lorincz
postulated that oxidative breakdown of squalene and
other skin lipids may not merely be a consequence of
the acne process. He suggested that lipid peroxides
might be directly ‘acnegenic to the skin’. Based on his
theory, it was hypothesized that antioxidants would be
of value in limiting and preventing the condition via
reduction in the formation of peroxides and other oxi-
dation products. In a small controlled pilot study (n =
15) he reported clinical success with topical alpha-toco-
pherol (0.05%) in acne after one month of evaluation by
an independent examiner [14]. While there had been
previous reports of clinical success with vitamins A and
C [15-19], Lorincz was the first to specifically consider
antioxidants to be of value in acne. The previous bene-
fits of what would turn out to be called antioxidant vita-
mins and flavonoids (including an 800 mg oral vitamin
C and hesperidin complex) were largely attributed to
support of normal keratinization [17,18].
Further support to the lipid peroxidation hypothesis
would come from University of California, Davis, scien-
tist Alloys L. Tappel, who reported in 1975 that lipid
peroxidation is evident in acne, and that localized free
radical damage and peroxides might be involved in initi-
ating the damaging inflammatory reactions [20]. Follow-
ing this, other investigators reported that components of
sebum, particularly squalene, show enhanced comedo-
genicity when oxidized [21]. Indeed, squalene was
reported to be highly sensitive to oxidation and
researchers reported that both squalene and its oxidized
metabolites are found at much higher levels in acne vs.
healthy controls [13,22-24]. University of California, Los
Angeles, dermatologist Samuel Ayres Jr. and colleague
Richard Mihan provided observational case reports indi-
cating benefit of the synergistic value of oral vitamins A
and E as a means to attenuate lipid peroxidation in
acne. They urged investigators to pursue the lipid perox-
idation hypothesis, suggesting that inflammation in acne
is a secondary event to lipid peroxidation. In 1978 Ayres
and Mihan commented ‘that the administration of an
antioxidant might be a logical and effective means of
controlling the inflammation by preventing oxidation of
lipids’ and ‘the subsequent release of irritating free radi-
cals into the tissues’ [25]. This was followed by preli-
minary reports of low blood levels of glutathione
peroxidase (GSH-Px), and its required mineral co-factor
selenium, among patients with acne [26-28]. It was also
noted, a quarter century ago, that the therapeutic value
of tetracycline antibiotics in acne might be due to their
ability to act as antioxidants [29]. These early findings
and the urging of Ayres and Mihan did not, however,
advance the lipid peroxidation theory into mainstream
dermatological discussions.
Contemporary Investigations - Systemic Oxidative
Stress
In recent years there has been renewed interest in the
influence of oxidative stress and the operations of the
antioxidant defense system in acne. Many of these inves-
tigations have examined the extent to which a potential
oxidative stress burden in the skin might be reflected in
the blood of acne patients. In a study involving 52
patients with papulopustular acne, researchers reported
that blood antioxidant enzyme activities, including
superoxide dismutase (SOD) and GSH-Px, were signifi-
cantly lower vs. controls [30]. Presumably, the decreased
activity is a result of the consistent burden of oxidative
stress. As we will discuss, the consumption of antioxi-
dants and the demand for antioxidant enzymatic activity
may not be a mere consequence of the downstream
clinical manifestations of acne. The lower blood GSH-
Px activity replicated the initial work of Michaelsson
and Edqvist 17 years earlier [27]. In addition, there was
evidence of an increased oxidative stress burden as
reflected in higher thiobarbituric acid reactive substance
(TBARS) levels in the acne patients. Separate investiga-
tions have also found elevated malondialdehyde (MDA)
[31], a reactive species well known to be a marker of
increased oxidative stress. Emerging studies indicate that
low blood SOD, GSH-Px and elevated MDA are charac-
teristic of acne vs. healthy controls [32-35]. These differ-
ences are not minute; indeed the GSH-Px activity in
adults with acne is reported to be 42 percent lower than
healthy controls [34]. Some investigators have not found
a blanket decrease in SOD and increase in MDA among
all acne patients. One investigative group noted that
p a t i e n t sw i t ht h em o r es e v e r ef o r m so fa c n eh a v et h e
lowest SOD and highest MDA levels vs. other milder
cases and controls [36].
Hydrogen peroxide is a reactive oxygen species (ROS)
produced by neutrophils, and as with other ROS, it is
well capable of promoting inflammation, causing tissue
damage and further lipid destruction. Hydrogen perox-
ide production was measured from whole blood samples
taken from adults with inflammatory acne vs. healthy
controls. Patients with inflammatory acne had signifi-
cantly higher production of hydrogen peroxide, 43%
more than healthy controls. After treatment with mino-
cycline there was a 25% reduction in whole blood,
microbial and chemically stimulated, neutrophil hydro-
gen peroxide production. Since the researchers used
both Staphylococcus aureus and phorbol myristate
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difference in neutrophil response to microbes vs. chemi-
cal stimulation in acne), it appears that the ROS gener-
ating system is primed for accelerated production in
acne [37]. Also, since minocycline and other tetracycline
antibiotics are now known to have clear antioxidant
properties, particularly in reducing lipid peroxidation in
potency similar to vitamin E [38], the results lend
further support to the suggestion - 17 years earlier -
that this class of antibiotics may be helping via non-
antimicrobial pathways in reduction of ROS. Indeed, a
recent investigation showed that doxycycline, at sub-
antimicrobial doses, reduced papules and pustules by
over 80% after 3 months in those with moderate facial
acne [39].
Some of the emerging studies have also measured
plasma and serum levels of antioxidant nutrients in acne
patients. Among 100 newly diagnosed and untreated
acne patients, plasma levels of vitamins A and E were
significantly lower than controls. Indeed, the severity of
acne showed a negative correlation with blood antioxi-
dants, such that the vitamin A levels in those with the
most severe acne were 52% lower and the vitamin E
levels were 31% lower vs. healthy age-matched controls
[ 4 0 ] .L o ws e r u ml e v e l so fv i t a m i n sAa n dE ,a sw e l la s
beta-carotene and vitamin C, have also been reported in
a group of 45 female acne patients vs. healthy controls
(respectively vitamin A 33%, vitamin C 40%, vitamin E
46%, beta-carotene 64% lower on average) [41]. Low
serum levels of vitamin A in untreated acne patients
had been previously documented in 1978 [42]. The con-
temporary investigation also added in an additional
blood enzyme as an end-point - platelet monoamine
oxidase (MAO) - the activity of which has been impli-
cated in a variety of mental health disorders, including
anxiety and depression. The investigators found low
MAO activity in acne, a finding which, while not univer-
sal, is consistent with previous investigations in affective
d i s o r d e r s[ 4 3 ] .A sw ew i l ld i s c u s ss h o r t l y ,t h i sf i n d i n g
has enormous implications in the lipid peroxidation the-
ory of acne and its overlap with the emerging research
showing oxidative stress is not a mere consequence of
mental health disorders.
Emerging Research within Experimental
Dermatology
Although the recent studies on blood markers of oxida-
tive stress in acne are of importance, they are limited in
that they provide no insight into oxidative stress as a
causative agent or mere consequence of the disease. The
findings of increased systemic oxidative stress and
diminished blood levels of antioxidants in acne take on
greater meaning when placed in context of the new
findings within experimental dermatology. A series of
sophisticated bench studies have pointed to lipid peroxi-
dation as the match that lights the inflammatory process
in acne.
In support of previous research, it has become
increasingly clear that squalene production is highly
upregulated in acne. Overall acne patients have 59%
more sebum than healthy controls, yet it is squalene
that emerges as the specific lipid that is being produced
in abundance - 2.2-fold higher vs. controls [44]. As
expected, an increase in squalene sets the stage for sig-
nificantly higher levels of squalene peroxides and dimin-
ished vitamin E in the sebum of acne patients [45].
Squalene peroxides also diminish the important skin
antioxidant glutathione, while pre-treatment with glu-
tathione depleting agents (DL-buthionine sulfoximine
and diethyl maleate) makes the comedogenic potential
of squalene peroxides even worse [46]. In smokers with
acne the squalene peroxidation and vitamin E reduction
is even more pronounced [47]. Not only are the squa-
lene peroxides confirmed to be highly comeodogenic
[48], they have recently been reported to set an inflam-
matory cascade in motion. Specifically, exposure of per-
oxidated squalene products to human keratinocyte cells
stimulates production of inflammatory cytokines and
upregulates lipoxygenase (LOX) activity [49]. Consider-
ing that LOX activity, and leukotriene B4 (LTB4) in par-
ticular, has been implicated in promoting inflammation
in acne (even in the absence of Propionibacterium
acnes), this was an important discovery. LTB4 is a che-
moattractant well capable of recruiting ROS-generating
neutrophils, and its inhibition has been shown to
improve acne in clinical research [50,51].
Researchers have also had a closer look at the
mechanisms through which P. acnes promotes inflam-
mation in acne. Once again, it appears rooted in the
initial production of ROS. When keratinocytes are
exposed to P. acnes surface proteins there is an immedi-
ate generation of ROS, most notably superoxide. The
superoxide is handled by SOD which converts it into
hydrogen peroxide, and then GSH-Px is called upon to
dispose of the hydrogen peroxide by converting it into
water [52]. Obviously, this study can provide rationale
as to why SOD and GSH-Px might become exhausted
due to the burden of oxidative stress, particularly in
more severe forms of acne. In addition, the researchers
discovered that drugs and nutrients with anti-acne activ-
ity - isotretinoin, retinol, zinc sulfate - showed signifi-
cant inhibition of the P. acnes-stimulated superoxide
production. The authors conclude, as others have
before, that inhibition of inflammation ‘using appropri-
ate antioxidant molecules could be considered as poten-
tial treatment of acne’ [52].
Additional research seems to confirm that lipid perox-
idation is the driving force behind the progression of
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of comedo samples (20-30 comedones from each
patient) removed from acne patients shows that lipid
peroxidation is evident even in the earliest microco-
medo. As the disease progresses to inflamed lesions
there is an up to 4-fold increase in lipid peroxide levels
[53]. The marked increase in lipid peroxidation once
inflammation is ongoing is to be expected. Undoubtedly
ROS can provoke the secretion of inflammatory cyto-
kines; however, once initiated, inflammatory chemicals
cause a subsequent increase in ROS production [54].
Agents with anti-inflammatory activity are important in
the reduction of ROS activity, yet the new findings sug-
gest that antioxidants may provide therapeutic efficacy
closer to the root.
Lipid Peroxidation, Acne and Mental Health
As mentioned previously, the rates of depression and
anxiety in acne are much higher than that of healthy
controls. It would be simple to write this off as a conse-
quence of a disease that, in most cases, presents itself in
such a visible way. Such a view is largely justifiable.
There is no question that the development of acne, or
any visible skin disease, can induce depressive symptoms
and anxiety, particularly social anxiety. Yet, might it also
be true that mood-related symptoms pre-date or even
set the stage for a higher propensity to acne? Might the
physiological pathways involved in promoting suscept-
ibility to acne also promote a greater generalized risk of
mental health disorders? Why is it that despite marked
clinical success with topical and oral interventions, a
number of studies using validated measurements of
depression, mood and quality of life, indicates that the
mental outlook remains unchanged [55-58]? Indeed, in
one of the studies cited [55], mood scores declined
despite significant clinical improvement with topical
interventions. In a systematic review examining depres-
sion and isotretinoin, only 1 out of 4 studies using vali-
dated depression instruments showed a statistically
significant reduction in depressive symptoms [59]. It
seems remarkable that an agent with such obvious clini-
cal benefit would only show a trend toward improving
depressive symptoms and mental outlook. Some derma-
tologists have pondered this paradox over the years, as
did William O. Roop who, after detailed review of clini-
cal histories, commented in 1921 that ‘Ia ml e dt o
believe that this depression precedes the acne, and is
more of a causal factor than it is a resultant of the dis-
ease’ [60]. Some groups have focused on the influence
of life stressors in acne development or exacerbation
[61]. It has been postulated that differences in personal-
ity features which predate the onset of acne might lead
to greater stress reactivity and vulnerability to acne
[62-65].
Famed British physician Sir Charles Blackburn theo-
rized in 1951 that unknown endogenous factors may be
driving higher rates of psychoneurogenic disturbances in
acne [66]. While acknowledging that the disease itself
can undoubtedly cause mental distress, his contention
was that certain groups of acne patients ‘must have a
previous liability’ to mental health disorders, and that
such liability may be acted upon by internal factors that
have yet to be determined. The end result, according to
his liability theory, was an increased risk of diagnosable
mental health disorders in acne. With this background,
the new findings in the area of lipid peroxidation and
acne cannot be viewed in isolation, particularly since a
similar line of evidence continues to mount in the field
of mental health, one linking lipid peroxidation with
depression and anxiety [67]. It is our hypothesis that
oxidative stress may be a key endogenous factor causing
a pronounced liability to anxiety and depression among
acne patients.
If there is enhanced systemic oxidative stress and lipid
peroxidation in acne, and the serum/plasma human stu-
dies discussed above can only suggest that this is indeed
the case, there would be every likelihood of changes to
mitochondrial function, membrane fluidity and changes
to enzymes and ion channel functioning within the ner-
vous system. Oxidative stress can also compromise nor-
mal production of brain growth factors, levels of which
have been inversely associated with risk of depression
and anxiety. Even small increases in oxidative stress, and
lipid peroxidation in particular, may be a causative fac-
tor in depression and anxiety [68-70]. Oxidative stress
may not be a mere consequence of mental health disor-
ders, as recent experimental studies show that inten-
tional induction of oxidative stress can significantly
increase behavioral changes indicative of anxiety [71].
Induction of oxidative stress also increases blood insulin
levels, an additional factor pertaining to acne and
depression which we will discuss shortly.
We are struck by the similarity (vs. acne) of greater
demands upon SOD enzymes and GSH-Px activity, as
well as elevated MDA in the periphery of patients with
affective disorders [72,73]. Blood levels of antioxidant
nutrients have been shown to be low in clinical depres-
s i o n[ 7 4 ] .W ea l s of i n di tn o t e w o r t h yt h a tt w oa n t i o x i -
dant co-factoring minerals - zinc and selenium - are low
in both acne and depression [75-77]. It hints further at
an increased nutrient demand in conditions related to
systemic oxidative stress. Indeed, zinc has been the sub-
ject of recent clinical investigations in both acne and
depression and it has been shown to improve outcome
in treatment-resistant depression [78,79].
Older studies indicate that oral vitamin D has thera-
peutic value in acne [80-82], and emerging studies are
showing that topical vitamin D analogues have
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min D has antioxidant properties, can increase SOD and
GSH-Px activity [84,85], and low levels are associated
with symptoms of depression and anxiety [86,87]. While
there has been much discussion on the influence of
excess vitamin A and isotretinoin in mood disturbances,
it is also evident that vitamin A deficiencies can result
in depressive behaviors [88]. Vitamin C has also been
recently reported to have anti-depressant activity in
experimental settings and epidemiological investigations
[89,90]. Keeping in mind that the human studies dis-
c u s s e da b o v es h o w e dt h a tu n t reated patients with acne
have low blood levels of vitamin A and C, a connection
to depression cannot be dismissed.
Over the last few years it has become clear that anti-
depressant agents, including various serotonin reuptake
inhibitors (SSRIs), possess ROS-scavenging properties
and prevent declines in SOD activity in conditions of
increased lipid peroxidation [91-93]. A recent human
study has shown that oral supplementation with a
microencapsulated SOD improved cognition, irritability
and mental outlook vs. placebo after four weeks [94]. In
addition, experimental studies suggest that dietary plant-
based antioxidants can influence neurotransmitter avail-
ability and protect against stress-induced behavioral
changes [95-99]. Finally, antioxidant components of the
diet may protect against depression [100,101], and
greater adherence to a Mediterranean-style diet rich in
antioxidants has been shown to reduce the 5-year risk
of depression by approximately 30 percent [102].
In one population study involving 18-19 year-old stu-
dents in Norway, researchers reported no connection
between ‘fatty fish’ consumption, acne and mental dis-
tress [103]. Unfortunately the authors relied upon diet-
ary recall methods without validated nutritional
instruments and did not define ‘fatty fish’ to the partici-
pants - almost certainly why 93 percent of the sample
claimed to have consumed fatty fish only on rare occa-
sion. In addition, they found a self-report acne preva-
lence of only 13.6 percent for teenage males and
females, much lower than would be expected in Wes-
tern nations. Ultimately the determination of depression
and anxiety as risk factors for acne can only be assessed
by prospective studies, such as those that have indicated
depressive symptoms and anxiety in normal-weight
youth can pre-date subsequent risk for later obesity
[104,105]. In the meantime, it is our contention that
over-lapping lipid peroxidation may be taxing to the
antioxidant defense system in both acne and depression.
This may tip the scale to further damage and inflamma-
tion at the sebaceous gland, and also, at the same time,
negatively influence neuronal communication. Ulti-
mately this may set the stage for higher rates of depres-
sion and anxiety in acne. Preliminary reports of clinical
success in acne treatment with antidepressant medica-
tion as monotherapy [106,107] should encourage
detailed exploration of the brain-skin axis. It may be the
case that certain acne-prone individuals, or a subset of
acne patients, are primed for lipid peroxidation long
before depression and acne become clinically apparent.
Clinical Implications
Based on the above discussions, it would seem reason-
able that clinical interventions with oral and topical
agents designed to support the antioxidant defense sys-
tem would be helpful in acne. For now, the bench inves-
tigations have not stimulated large-scale clinical trials to
determine if antioxidants can limit the acne process or
augment the value of other first line acne interventions.
Although sparse, a few preliminary studies have pro-
vided encouraging results and suggest that an internal-
topical combination of antioxidants might be the most
suitable clinical approach.
An emerging candidate is the stable vitamin C precur-
sor, sodium ascorbyl phosphate (SAP), an agent which
has been shown to reduce sebum oxidation products by
up to 40%. A preliminary open-label study involving 60
acne patients used 5% SAP (applied twice daily) and
showed superior efficacy and tolerance after 12 weeks
vs. 5% benzoyl peroxide (BP) [108]. It was also reported
in a second open-label study that 5% SAP was more
effective than 1% clindamycin in the overall and inflam-
matory lesion counts after 12 weeks [109]. This was fol-
lowed up recently by randomized double-blind
intervention studies. The first showed that 5% SAP
reduced inflammatory acne lesions 49% after 8 weeks, a
result that was slightly enhanced by the co-administra-
tion of SAP and 0.2% retinol. The combination reduced
inflammatory lesions by 63% over the same period
[110]. The most recent study showed that 61% of
patients treated with 5% SAP lotion showed improve-
ment in the Investigator’s Global Assessment Score
(IGAS) and 71% improved as measured by the Subjects’
Global Assessment Score (SGAS). These results were in
contrast with the group receiving the placebo vehicle
lotion where the reports were 38% improvement via
IGAS and 52% via the SGAS at the end of the 12-week
study [111].
Green tea is a source of plant-based antioxidants, par-
ticularly the catechins which are well known to prevent
local and systemic declines in SOD and GSH-Px activity,
as well as attenuating lipid peroxidation [112,113].
A recent clinical study has reported value of a topical
(2%) green tea lotion in mild-to-moderate acne. The
open-label study showed that twice-daily application of
the green tea lotion reduced total lesion count by 58%
after 6 weeks [114]. A similar study using a 2% tea
(unspecified type of tea) lotion found that it was more
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reduction of acne lesions after 8 weeks [115]. It should
be pointed out that there are multiple mechanisms
whereby green tea may be therapeutic in acne - anti-
inflammatory activity, anti-microbial activity against P.
acnes, and a potential ability to reduce sebum produc-
tion via 5-a-reductase inhibition [116,117]. In any case,
the antioxidant activity of green tea and its catechins
warrant further investigation.
Additional support for the use of topical antioxidants
is found in a recent open-label trial of the antioxidant
agent fullerene. It has been reported that fullerene, a
spherical carbon molecule with a unique cage structure
capable of acting as a sponge to free radicals, has anti-
oxidant activity several hundred times higher than vita-
min-based antioxidants. In particular, fullerene can
protect against lipid peroxidation. A 1% fullerene gel
applied twice daily reduced the number of inflammatory
lesions by 38% during the 8-week investigation. While
small (n = 11) and without a placebo control, this pilot
investigation in adults with acne suggests potential value
of fullerene as a topical antioxidant therapy [118].
Zinc and nicotinamide are both nutrients which sup-
port antioxidant pathways [119,120], and preliminary
clinical trials show value in topical application. Zinc is
well known to enhance efficacy of topical antibiotics,
while a 4% nicotinamide gel has been shown to outper-
form 1% clindamycin gel when applied twice daily for
12 weeks (82% vs. 68% improvement respectively) [121].
There are a limited number of small studies indicating
value of oral zinc in acne, the most recent showing that
30 mg of zinc gluconate reduces total inflammatory
lesion count by 57% after two months [122]. In the
open-label Nicomide Improvement in Clinical Outcomes
Study (NICOS) an oral nutrient combination (750 mg
nicotinamide, 25 mg zinc, 1.5 mg copper, 500 mcg folic
acid) taken daily for eight weeks appeared to be effective
and well tolerated. After four weeks 79% of the subjects
demonstrated at least moderate improvement, and the
addition of oral antibiotic therapy to one subgroup (51
of the total n of 198) did not provide any additional
clinical benefit [123].
An oral multi-nutrient antioxidant agent has been the
subject of a recent 12-week preliminary trial involving
48 patients with acne. The antioxidant capsule was
taken tid for a daily total of 45 mg zinc, 180 mg vitamin
C, 18 mg mixed carotenoids, 45 IU d-alpha-tocopherol
acetate and 390 mcg of chromium. Significant improve-
ments were noted in physician evaluations after 8
weeks, and after 12 weeks 79% of the patients were
found to have an 80% or more improvement. As this
was an open-label study, broad conclusions cannot be
made concerning the outcome. It is interesting to note,
however, that the clinical benefits did not appear until
2 to 3 months after internal consumption of the agent
[124]. This implies that the use of internal agents may
take time. Indeed oral vitamin E consumption can take
weeks before sebum levels are significantly elevated
[125]. The addition of mixed carotenoids, presumably
inclusive of lycopene, is theoretically sound. Lycopene
can reduce lipid peroxidation and it can support SOD
and GSH-Px activity [126,127]. Related carotenoids such
as lutein and zeaxanthin are also of potential value since
they can reduce lipid peroxidation in the skin [128]. It
could be speculated that another lipophilic antioxidant,
co-enzyme Q10, found in skin surface lipids, would be
of therapeutic value [129].
Lactoferrin, a dairy-based glycoprotein with strong
antioxidant activity [130,131], has also been the subject
of a recent clinical trial in acne. In a 12-week double-
blind, placebo-controlled study, the oral consumption of
200 mg of lactoferrin reduced total lesion count by 23%
over placebo. The inflammatory lesion count declined
by over 38% during the course of the three months. In
support of the total lesion reduction, the severity of
acne according to the Leeds Acne Grading System
declined 20% compared with placebo [132].
The global aspects of diet are also worthy of brief
mention. In recent years it has become evident that
there may indeed be a connection between dietary com-
ponents and the risk of acne. For example, regional
diets low in processed foods and sugars (with an overall
low glycemic load) are associated with decreased acne
risk [133]. Intervention studies using similar low glyce-
mic load meals have reported improvements [134]. One
of the features of these intervention studies is that they
tend to be higher in ‘nutrient-dense’ foods, and this
would include greater intake of plant-based antioxidants
from whole grains, vegetables and fruits. Adherence to
the so-called South Beach diet, similar to the Mediterra-
nean diet which reduces depression risk by 30%, has
been associated with the reduction and discontinuance
of acne medications [135].
Here again, we must make note of the connection
between oxidative stress, insulin and depression. As
mentioned above, induction of oxidative stress has been
s h o w nt oe l e v a t ei n s u l i nl e v e l s[ 7 1 ] ,a n di nt u r n ,i n s u l i n
itself increases oxidative stress within the skin and steps
up demand for SOD [136]. Even in healthy adults, epi-
demiological studies have made associations between
blood chemistry indicative of insulin resistance and an
elevated risk of depressive symptoms [137,138]. It has
been well documented that a period of insulin resistance
occurs during puberty [139], one coinciding with the
development of acne, depression and/or anxiety. There
is also a generalized increase in SOD activity, 25%
higher in a healthy 17-year old vs. a 7-year old [140].
These findings take on greater meaning when placed in
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acne is associated with increased consumption of highly
palatable, sweet, fried, calorie-rich foods with low nutri-
ent density [141-143]. Add to this experimental research
indicating that regular consumption of such a highly
palatable diet increases oxidative stress in the central
nervous system and promotes anxiety-like behavior
[144].
Benzoyl Peroxide and Antioxidants
One advantage of oral and/or topical antioxidant inter-
ventions may be their ability to augment standard care
in acne. An obvious application of antioxidants might
be the co-administration with BP, yet there are unan-
swered questions which must be clarified before indivi-
dual antioxidants are simply added to BP. Although BP
has been used widely for many years in dermatology,
and certainly there is evidence that it is helpful in acne,
it is not without side effects. It is also not without con-
troversy. In recent years there have been calls to take a
closer look at the negative consequences of BP therapy.
Experimental studies have shown that BP is cytotoxic
and capable of promoting the growth of skin tumors.
[145,146] A recent animal study showed that topical BP
increased mortality when combined with UV radiation
[147]. In one oft-cited study, BP was shown to reduce
the experimental production of ROS, although it did so
only by killing polymorphonuclear leucocytes that would
otherwise induce free radicals [148].
Although BP’s role as a tumor promoter has been well
established in several animal species, the significance of
these findings in humans remains unknown. There are
many substances which have potential carcinogenic
activity in rodents at high doses and yet do not appear
to increase risk or accelerate tumor progression in
humans. Thus far, the accumulated evidence, including
large-scale population studies, indicates that broad clini-
cal use of BP doses not increase skin cancer risk in
humans [149-151]. In our context, BP warrants discus-
sion because its clinical success has been linked with its
pro-oxidant activity [152,153]. Indeed, research shows
that BP causes major reductions in skin antioxidant
levels. Specifically, BP reduces epidermal vitamin E by
up to 95% and vitamin C by up to 70% [154].
Given that the sebaceous gland represents the major
physiologic route of delivery of one of the most protec-
tive agents for human skin - vitamin E - its near elimi-
nation by BP should be, at the very least, cause for
concern. Sebaceous gland vitamin E secretion has been
shown to be highest in areas where it would be advanta-
geous to have additional antioxidant support against
environmental assaults (e.g. ratio of facial vs. upper arm
epidermal vitamin E levels is 20:1) [155]. These findings
would certainly suggest that a simple addition of vitamin
E to BP would be rational. However, the co-administra-
tion of BP and vitamin E has been found, at least in
experimental conditions, to increase total ROS produc-
tion. In contrast, if vitamin E was used well in advance
of BP, then excellent protection against BP toxicity was
observed [156]. This study highlights the often-contra-
dictory findings in the area of free radical research, and
clearly shows that thorough investigations must be con-
ducted before bench work translates into clinical suc-
cess. Indeed a combination of vitamin E and the
glutathione precursor N-acetylcysteine seems to work
synergistically in reducing BP toxicity [157]. Obviously
t h e r ei sm u c hw o r kt ob ed o n eb e f o r eo r a la n dt o p i c a l
antioxidants can be broadly prescribed in acne. Inter-
vention studies indicating value of topical and oral anti-
oxidant preparations are, at present, far from robust, yet
there appears to be more than enough background data
to warrant a vigorous pursual of further research.
Back to the Future
Finally, as a historical note on the old wine, there are
older reports showing value of oral vitamins A, C, D, E,
and nicotinic acid in acne [158,159]. In today’se v i -
dence-based context these publications can only be
described as observational or case reports. They are lar-
gely from clinicians who followed patients and reported
value of certain nutrients over the span of years of clini-
cal experience. Some provided specific details, such as a
1954 report using a combination of 3 grams of ascorbic
acid and an 8-ounce glass of citrus juice as reported to
be of value in 53 patients with acne. Followed for four
months, 43 patients showed improvement, including 15
of which were described as previously treatment resis-
tant [17]. In 1959, a group of dermatologists followed 30
treatment-resistant patients who received 400 mg of
ascorbic acid and 400 mg of the flavonoid complex
hesperidin (Hesper-C) [18]. The physicians reported that
29 out of the 30 noted definite improvement when
Hesper-C was added to other therapies. The researchers
concluded the report by stating ‘it is hoped that a large
clinic will see fit to run a placebo-controlled study to
evaluate more critically the effects of hesperidin and
ascorbic acid in the treatment of acne.’ Over 50 years
later, and with more than ample justification, the time
may be right to initiate the long-awaited study.
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